Plerixafor hydrochloride. Chemokine CXCR4 (SDF-1) antagonist stem cell-mobilizing agent

Drugs of the Future

Volumn 32, Issue 2, 2007, Pages 123-136

  Davies, S L ^a   Serradell, N ^a   Bolos J ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); BUSULFAN; CARBOPLATIN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEPREDNISONE; MOZOBIL; PLERIXAFOR HYDROCHLORIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; SDZ SID 791; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOATING; CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; EWING SARCOMA; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE STINGING; MEDULLOBLASTOMA; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PARESTHESIA; PERIORAL PARESTHESIA; RABBIT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; VOMITING;

EID: 34247530304     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.02.1071897     Document Type: Review

References (106)

1. Ciampolini, M., Fabbrizzi, L., Perotti, A., Poggi, A., Seghi, B., Zanobini, F. Dinickel and dicopper complexes with N,N-linked bis(cyclam) ligands. An ideal system for the investigation of electrostatic effects on the redox behavior of pairs of metal ions. Inorg Chem 1987, 26(21): 3527-33.
2. Bridger, G.J., Skerlj, R.T., Thornton, D. et al. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem 1995, 38(2): 366-78.
3. Brandes, S., Gros, C., Denat, F., Pullumbi, P., Guilard, R. New facile and convenient synthesis of bispolyazamacrocyles using Boc protection. Determination of geometric parameters of dinuclear copper(II) complexes using ESR spectroscopy and molecular mechanics calculations. Bull Soc Chim Fr 1996, 133(1): 65-73.
4. Dessolin, J., Galea, P., Vlieghe, P., Chermann, J.-C., Kraus, J.-L. New bicyclam-AZT conjugates: Design, synthesis, anti-HIV evaluation, and their interction with CXCR-4 coreceptor. J Med Chem 1999, 42(2): 229-41.
5. Giandomenico, C.M., Yang, W. (AnorMED, Inc.). Process for preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof. WO 0226721.
6. Yan, W., Giandomenico, C.M., Sartori, M., Moore, D.A. Facile N-1 protection of cyclam, cyclen and 1,4,7-triazacyclonanene. Tetrahedron Lett 2003, 44: 2481-3.
7. Prashad, M., Kapa, P. (Johnson Matthey plc). Process for preparing 1,1′-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11- tetraazacyclotetradecane. WO 9634860.
8. Xu, D., Kapa, P., Repic, O., Blacklock, T.J. (Johnson Matthey plc). Process for preparing 1,1′-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11- tetraazacyclotetradecane. WO 9630349.
9. Xu, D., Mattner, P.G., Prasad, K., Repic, O., Blacklock, T.J. An expeditious synthesis of a biscyclam with an aromatic linker. Tetrahedron Lett 1996, 37(30): 5301-4.
10. Achmatowicz, M., Hegedus, L.S. Direct synthesis of 1,1′-[1,4-phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride (AMD 3100) without the use of protecting groups. J Org Chem 2003, 68(16): 6435-6.
11. Boschetti, F., Denat, F., Espinosa, E., Tabard, A., Dory, Y., Guilard, R. Regioselective N-functionalization of tetraazacycloalkanes. J Org Chem 2005, 70(18): 7042-53.
12. Handel, H., Yaouanc, J.-J., Zegzouti, A.F. et al. (Centre National de la Recherche Scientifique [CNRS]). Process for the preparation of monofunctionalized cyclic tetramines. US 5047527.
13. Yaouanc, J.-J., Le Bris, N., Le Gall, G., Clément, J.-C., Handel, H., des Abbayes, H. Mono N-functionalization of cyclic and linear tetraamines via their tridentate tricarbonylchromium complexes. J Chem Soc Chem Commun 1991, 206-7.
14. Guillaume, D., Marshall, G.R. Efficient one-pot synthesis of JM3100. Synth Commun 1998, 28(15): 2903-6.
15. Onuffer, J.J., Horuk, R. Chemokines, chemokine receptors and small-molecule antagonists: Recent developments. Trends Pharmacol Sci 2002, 23(10): 459-67.
16. Burger, J.A., Kipps, T.J. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107(5): 1761-7.
17. Aiuti, A., Webb, I.J., Bleul, C., Springer, T., Gutierrez-Ramos, J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997, 185: 111-20.
18. Peled, A., Petit, I., Kollet, O. et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283: 845-8.
19. null mice. Leukemia 2002, 16: 1992-2203.
20. Roberts, A.W., DeLuca, E., Begley, C.G., Basser, R., Grigg, A.P., Metcalf, D. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995, 13: 512-6.
21. De Clercq, E. Antiviral drug discovery and development: Where chemistry meets with biomedicine. Antiviral Res 2005, 67(2): 56-75.
22. Joao, H.C., De, V.K., Pauwels, R., De, C.E., Henson, G.W., Bridger, G.J. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J Med Chem 1995, 38(19): 3865-73.
23. Bridger, G.J., Skerji, R.T., Padmanabhan, S. et al. Structure-activity relationships in the anti-HIV activity of bis-azamacrocycles: Highly potent inhibitors of HIV replication with a unique mechanism of action. 207th ACS Natl Meet (March 13-17, San Diego) 1994, Abst MEDI-23.
24. Skerli, R.T., Bridger, G.J., Padmanabhan, S. et al. Synthesis and anti-HIV activity of aromatic linked bis-azamacrocycles. 207th ACS Natl Meet (March 13-17, San Diego) 1994, Abst MEDI-24.
25. De Clercq, E., Yamamoto, N., Pauwels, R. et al. Highly selective and potent inhibition of human immunodeficiency virus (HIV) by the novel bicyclam derivative JM3100. Antivir Res 1993, 20(Suppl. 1): Abst 3.
26. Datema, R., Abrams, M., Bridger, G. et al. SDZ SID 791 (JM 3100): A mechanistically unique anti-HIV agent with potent antiviral activity in vitro and in vivo. 34th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 4-7, Orlando) 1994, Abst F158.
27. Datema, R. SDZ SID 791 (JM 3100): A mechanistically unique anti-HIV agent with potent antiviral activity in vitro and in vivo. 10th Int Conf AIDS (Aug 7-12, Yokohama) 1994, Abst 113A.
28. Hatse, S., Princen, K., Bridger, G., De Clercq, E., Schols, D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527(1-3): 255-62.
29. Gerlach, L.O., Skerlj, R.T., Bridger, G.J., Schwartz, T.W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001, 276(17): 14153-60.
30. Donzella, G.A., Schols, D., Lin, S.W. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998, 4: 72-7.
31. Hendrix, C.W., Collier, A.C., Lederman, M.M. et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004, 37(2): 1253-62.
32. Broxmeyer, H.E., Hangoc, G., Cooper, S., Bridger, G. Interference of the SDF-1/CXCR4 axis in mice with AMD3100 induces rapid high level mobilization of hematopoietic progenitor cells, and AMD3100 acts synergistically with G-CSF and MIP-1α to mobilize progenitors. Blood 2001, 98(11, Part 1): Abst 3371.
33. Rosenkilde, M.M., Gerlach, L.O., Jakobsen, J.S., Skerlj, R.T., Bridger, G.J., Schwartz, T.W. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: Transfer of binding site to the CXCR3 receptor. J Biol Chem 2004, 279(4): 3033-41.
34. Broxmeyer, H.E., Orschell, C.M., Clapp, D.W. et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201(8): 1307-18.
35. Broxmeyer, H.E., Cooper, S., Hangoc, G., Bridger, G. AMD3100, an antagonist of CXCR4, is a potent myeloid progenitor cell mobilizing agent in mouse strains differing in response to G-CSF-induced mobilization, and synergizes with G-CSF in these mice to enhance mobilization. Exp Hematol 2002, 30(6, Suppl. 1): Abst 34.
36. Broxmeyer, H.E., Hangoc, G., Cooper, S., Li, X., Bridger, G., Clapp, D.W. AMD3100, an antagonist of CXCR4 and mobilizer of myeloid progenitor cells, is a potent mobilizer of competitive repopulating long term marrow self-renewing stem cells in mice. Blood 2002, 100(11, Part 1): Abst 2397.
37. van Os, R., Schols, D., Struyf, S., De Clercq, E., Willemze, R., Fibbe, W.E. The CXCR4 antagonist AMD3100 does not prevent homing and engraftment of murine syngeneic bone marrow stem cells. Blood 2000, 96(11, Part 2): Abst 5074.
38. + cells mobilized by G-CSF. Blood 2004, 104(11, Part 1): Abst 1186.
39. Devine, S.M., Liu, F., Holt, M., Link, D., DiPersio, J.F. AMD3100-mobilized murine hematopoietic stem cells and T-lymphocytes have identical capacity to induce multilineage stem cell engraftment, donor T-cell chimerism and GVHD in mice compared with G-CSF mobilized cells. Blood 2003, 102(11, Part 1): Abst 3495.
40. Rettig, M., Holt, M., Liu, F., Ritchey, J., Link, D., Bridger, G., DiPersio, J. Evaluation of the phenotype and GVHD-inducing potential of splenic T cells isolated from G-CSF, AMD3100, or G-CSF and AMD3100 pretreated allogeneic donors. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 5224.
41. Lundqvist, A., Hamoui, N., Andersson, J. et al. Allograft cell content and GVHD differ in murine recipients of AMD3100 versus G-CSF mobilized peripheral blood stem cells. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 3108.
42. Gai, B.Q., Holt, M.S., Nervi, B., Rettig, M.P., Ritchey, J.K., Bridger, G., DiPersio, J.F. Kinetics of hematopoietic progenitor cell mobilization with cyclophosphamide or cyclophosphamide plus AMD3100 using a mouse model. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 5217.
43. Burroughs, L., Mielcarek, M., Little, M.T. et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005, 106(12): 4002-8.
44. Larochelle, A., Krouse, A., Metzger, M. et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006, 107(9): 3772-8.
45. Larochelle, A., Krouse, A., Orlic, D., Donahue, R., Dunbar, C., Hematti, P. The use of AMD3100 mobilized peripheral blood stem cell CD34+ targets for retroviral transduction results in high-level in vivo marking in rhesus macaques. Blood 2003, 102(11, Part 2): Abst 5315.
46. Proulx, C., El-Helou, V., Gosselin, H., Clement, R., Calderone, A. Antagonism of the stromal cell-derived factor 1-alpha receptor CXCR4 reduced scar size and improved ventricular function in myocardial infarcted rats. Circulation [Am Heart Assoc Sci Sess (Nov 13-16, Dallas) 2005] 2005, 112(17, Suppl. 2): Abst 849.
47. Iwakura, A., Luedemann, C., Kusano, K., Takenaka, H., Eaton, E. AMD3100, a CXCR4 antagonist, augments mobilization and incorporation of bone marrow-derived endothelial progenitor cells into sites of myocardial neovascularization. Circulation 2003, 108(17, Suppl. 4): Abst 752.
48. Iwakura, A., Yamaguchi, J., Luedemann, C., Asahara, T., Losordo, D., Bridger, G. AMD-3100, a CXCR4 antagonist, augments incorporation of bone marrow-derived endothelial progenitor cells into sites of myocardial neovascularization. Blood 2002, 100(11, Part 1): Abst 1127.
49. Hu, J., Andersson, S., Orlic, D., Dunbar, C. Contrast in the mobilization of hematopoietic versus endothelial progenitors by AMD3100 in a rhesus macaque infarction model. Blood 2003, 102(11, Part 2): Abst 4332.
50. Ghobrial, I.M., Melhem, M., Singha, U. et al. The role of the CXCR4 inhibitor AMD3100 in multiple myeloma (MM). Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 2492.
51. Paul, S., Mancuso, P., Rabascio, C. et al. In vitro preclinical activity of the novel AMD3100 CXCR4 antagonist in lymphoma models. Blood 2002, 100(11, Part 1): Abst 2276.
52. Liesveld, J.L., Lancet, J.E., Rosell, K.E., Bechelli, J., Abboud, C.N., Phillips, G.L. The CXCR4 antagonist, AMD3100, inhibits AML transmigratory activity but does not alter blast proliferation or survival. Blood 2004, 104(11, Part 1): Abst 2881.
53. Juarez, J., Bradstock, K.F., Gottlieb, D.J., Bendall, L.J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003, 17(7): 1294-300.
54. Lagneaux, L., Delforge, A., Dejeneffe, M., Schols, D., Bron, D. The SDF-1/CXCR4 pathway is involved in the homing of chronic lymphocytic leukemia B cells and in their survival after migration into bone marrow stromal layers: Inhibition by the CXCR4 antagonist (AMD3100). Exp Hematol 2002, 30(6, Suppl. 1): Abst 72.
55. Rubin, J.B., Kung, A.L., Klein, R.S. et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003, 100(23): 13513-8.
56. Rubin, J.B., Kung, A.L., Klein, R.S. et al. Systemic delivery of a small molecule inhibitor of CXCR4 blocks the growth of intracranial xenografts of glioblastoma multiforme and medulloblastoma. Neuro-Oncol 2003, 5(4): Abst ET-41.
57. Rubin, J.B., Kung, A.L., Klein, R.S. et al. Systemic delivery of a small molecule inhibitor of CXCR4 blocks the growth of intracranial xenografts of glioblastoma mutliforme. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd ed): Abst R2772.
58. Toegel, F.E., Hu, Z., Westenfelder, C. Blocking CXCR4, the receptor for SDF-1, in mice with ischemic acute renal failure (ARF) improves renal function and survival. 38th Annu Meet Am Soc Nephrol (ASN) (Nov 8-13, Philadelphia) 2005, Abst F-PO292.
59. Nervi, B., Holt, M., Rettig, M.P., Bridger, G., Ley, T.J., DiPersio, J.F. In vivo bioluminescence imaging of acute promyelocytic leukemia cell trafficking and mobilization by AMD3100. Annu Meet Am Soc Blood Marrow Transplant (ASBMT) (Feb 16-20, Honolulu) 2006, Abst 44.
60. Nervi, B., Holt, M., Rettig, M.P., Bridger, G., Ley, T.J., DiPersio, J.F. AMD3100 mobilizes acute promyelocyte leukemia cells from the bone marrow into the peripheral blood and sensitizes leukemia cells to chemotherapy. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 246.
61. Lukacs, N.W., Berlin, A., Schols, D., Skerlj, R.T., Bridger, G.J. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002, 160(4): 1353-60.
62. De Klerck, B., Geboes, L., Hatse, S. et al. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther 2005, 7(6): R1208-20.
63. De Klerck, B., Hatse, S., Kelchtermans, H. et al. Pro-inflammatory properties of stromal cell-derived factor-1 (SDF-1, CXCL12) in collagen-induced arthritis, and inhibition by a specific CXCR4 antagonist. 4th Int Congr Autoimmun (Nov 3-7, Budapest) 2004, Abst.
64. Matthys, P., Hatse, S., Vermeire, K. et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-γ receptor-deficient mice. J Immunol 2001, 167(8): 4686-92.
65. Hendrix, C., Flexner, C., MacFarland, R., Giandomenico, C., Schweitzer, Henson, G. Chemokine CXCR-4 receptor blocker. AMD-3100: Clinical and pre-clinical studies of pharmacokinetics and safety. 6th Conf Retroviruses Opportunistic Infect (CROI) (Jan 31-Feb 4, Chicago) 1999, Abst 610.
66. Witvrouw, M., Seifert, J.-M., Henson, G.W., Martellucci, S.A., Desmyter, J., De Clercq, E. Pharmacokinetics of the anti-HIV bicyclam SID791 (JM3100) in rabbits, as determined by both analytical and bio-assay methods. Antivir Chem Chemother 1996, 7(1): 27-30.
67. Hendrix, C.W., Flexner, C., MacFarland, R.T. et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000, 44(6): 1667-73.
68. + hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 2005, 77(5): 427-36.
69. Green, B., Lee, H., Lack, N. et al. A population pharmacokinetic/ pharmacodynamic model for the mobilization of progenitor cells by AMD3100. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 2-6, Orlando) 2005] 2005, 77(2): Abst PII-160.
70. Green, B., Lee, H., Lack, N. et al. Use of an indirect effect model to describe the mobilization of progenitor cells induced by AMD3100. 14th Meet Popul Approach Group Eur (June 16-17, Pamplona) 2005, Abst P-11.
71. Lack, N.A., Dale, D.C.;, Calandra, G., MacFarland, R.T., Badel, K., Liles, W.C. A pharmacokinetic/pharmacodynamic profile of the CXCR4 antagonist AMD3100 for the mobilization of hematopoietic progenitor cells. Blood 2003, 102(11, Part 1): Abst 391.
72. Dale, D.C., Rodger, E., Christensen, J.J., Dehner, C., Badel, K., Calandra, G.B., Liles, W.C. Optimizing the use of AMD3100, a CXCR-4 antagonist, for mobilization of hematopoietic progenitor cells: Studies on healthy volunteers. Blood 2003, 102(11, Part 1):Abst 123.
73. Liles, W.C., Broxmeyer, H.E., Rodger, E. et al. Leukocytosis and mobilization of pluripotent hematopoietic progenitor cells in healthy volunteers induced by single dose administration of AMD-3100, a CXCR4 antagonist. Blood 2001, 98(11, Part 1): Abst 3071.
74. Liles, W.C., Broxmeyer, H.E., Rodger, E. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102(8): 2728-30.
75. Liles, W.C., Rodger, E., Broxmeyer, H.E. et al. Mobilization and collection of CD34+ progenitor cells from normal human volunteers with AMD-3100, a CXCR4 antagonist, and G-CSF. Blood 2002, 100(11, Part 1): Abst 404.
76. Liles, W.C., Rodger, E., Broxmeyer, H.E. et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45(3): 295-300.
77. Devine, S.M., Flomenberg, N., Vesole, D.H. et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004, 22(6): 1095-102.
78. Stiff, P., Micallef, I., McCarthy, P. et al. AMD3100 combined with standard doses of G-CSF leads to rapid, consistent mobilization of hematopoietic progenitor cells in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma. Blood 2004, 104(11, Part 1): Abst 2847.
79. Flomenberg, N., DiPersio, J., Liesveld, J. et al. AMD3100 + G-CSF hematopoietic progenitor cell (HPC) mobilization is safe, effective, and superior to mobilization with G-CSF alone. Blood 2003, 102(11, Part 1): Abst 124.
80. Flomenberg, N., Devine, S.M., DiPersio, J.F. et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106(5): 1867-74.
81. Stiff, P., Micallef, I., McCarthy, P. et al. AMD3100 plus G-CSF rapidly mobilizes hematopoietic progenitor cells in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), including those traditionally considered "poor mobilizers". Annu Meet Am Soc Blood Marrow Transplant (ASBMT) (Feb 10-14, Keystone) 2005, Abst 271.
82. Fruehauf, S., Seeger, T., Topaly, J. et al. The CXCR4-antagonist AMD3100 augments the number of mobilized peripheral blood progenitor cells (PBPC) when added to a G-CSF standard mobilization regime and AMD3100-mobilized PBPC result in rapid hematopoietic reconstitution after autologous transplantation. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 1961.
83. Fruehauf, S., Seeger, T., Topaly, J. et al. AMD3100 augments the number of mobilised peripheral blood progenitor cells when added to a G-CSF standard mobilisation regime and AMD3100-mobilised PBPC result in rapid haematopoietic reconstitution after autologous transplantation. 31st Annu Meet Eur Group Blood Marrow Transplant (EBMT) (March 20-23, Prague) 2005, Abst O275.
84. Seeger, T., Maier, P., Li, L., Laufs, S. et al. CD34+ cells mobilized with the new CXCR4 antagonist AMD3100 + G-CSF show increased anti-apoptotic, cell cycle, DNA repair and cell motility-associated gene expression when compared to G-CSF mobilization alone. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 4264.
85. Fruehauf, S., Seeger, T., Maier, P. et al. AMD3100 mobilises CD34+ cells with increased anti-apoptotic, cell cycle, DNA repair and cell motility-associated gene expression when compared to G-CSF mobilisation alone. Bone Marrow Transplant [32nd Annu Meet Eur Group Blood Marrow Transplant (EBMT) (March 19-22, Hamburg) 2006] 2006, 37(Suppl. 1): Abst P805.
86. Oelschlaegel, U., Bomhauser, M., Kroschinsky, F., Calandra, G., Ehninger, G., Platzbecker, U. Can CXCR-4 expression, analysed by flow cytometry, predict efficacy of stem cell mobilisation in patients receiving G-CSF plus AMD3100? Bone Marrow Transplant [32nd Annu Meet Eur Group Blood Marrow Transplant (EBMT) (March 19-22, Hamburg) 2006] 2006, 37(Suppl. 1): Abst P806.
87. Oelschlaegel, U., Bornhauser, M., Kroschinsky, F., Calandra, G., Ehninger, G., Platzbecker, U. Comparison of CXCR-4 and adhesion molecule expression in healthy bone marrow with expression in bone marrow and peripheral blood of patients receiving G-CSF plus AMD3100. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 1974.
88. Gazitt, Y., Freytes, C.O., Akay, C., Besinger, W., Badel, K., Calandra, G. Improved mobilization of CD34+ peripheral blood stem cells (PBSC) and dendritic cells (DCs) by AMD-3100 (AMD) in hard to mobilize non-Hodgkin's lymphoma (NHL patients (pts) mobilized with standard dose of G-CSF. Blood 2004, 104(11, Part 1): Abst 2856.
89. Cashen, A., Devine, S., Vij, R., DiPersio, J. AMD3100 + G-CSF improves hematopoietic progenitor cell (HPC) collection in patients with Hodgkin's disease (HD). Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 1979.
90. Devine, S.M., Bonde, J., Hess, D.A. et al. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Blood 2004, 104(11, Part 1): Abst 3341.
91. Andritsos, L.A., Edwards, T., Sempek, D. et al. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Annu Meet Am Soc Blood Marrow Transplant (ASBMT) (Feb 10-14, Keystone) 2005, Abst 14.
92. Devine, S.M., Andritsos, L., Edwards, T., Calandra, G., Bridger, G., DiPersio, J.F. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. 11th Annu Meet Int Soc Cell Ther (ISCT) (May 5-6, Vancouver) 2005, Abst 212.
93. Devine, S.M., Andritsos, L., Edwards, T., Calandra, G., Bridger, G., DiPersio, J.F. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Exp Hematol [34th Annu Sci Meet Int Soc Exp Hematol (July 30-Aug 2, Glasgow) 2005] 2005, 33(7, Suppl. 1): Abst 344.
94. Devine, S.M., Andritsos, L., Todt, L. et al. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 299.
95. Devine, S.M., Todt, L., Bonde, J. et al. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Annu Meet Am Soc Blood Marrow Transplant (ASBMT) (Feb 16-20, Honolulu) 2006, Abst 90.
96. McCarty, J., McGuirk, J., Grove, B., Badel, K., Olsen, H., Bridger, G., Calandra, G. AMD3100 plus G-CSF use in 100 proven poor mobilisers in a compassionate use protocol. Bone Marrow Transplant [32nd Annu Meet Eur Group Blood Marrow Transplant (EBMT) (March 19-22, Hamburg) 2006] 2006. 37(Suppl. 1):Abst O260.
97. Stephen, K., Montgomery, K., Bateman, C., Calandra, G., Shaw, P.J. Successful mobilisation, harvest and transplant of stem cells following AMD3100 in 3 paediatric patients. The Australian experience. Annu Meet Am Soc Blood Marrow Transplant (ASBMT) (Feb 16-20, Honolulu) 2006, Abst 457.
98. Dugan, M., Akard, L., Thompson, J. et al. Treatment with AMD3100 in multiple myeloma or non-Hodgkin's lymphoma patients to increase the number of peripheral blood stem cells when given with a mobilising regimen of chemotherapy and G-CSF. 31st Annu Meet Eur Group Blood Marrow Transplant (EBMT) (March 20-23, Prague) 2005, Abst P503.
99. Mobilization of stem cells with AMD3100 in non-Hodgkin's lymphoma patients (NCT00103610). ClinicalTrials.gov Web site, February 6, 2007.
100. Genzyme completes tender offer for outstanding shares of AnorMED. Genzyme Corp. Press Release, November 7, 2006.
101. Safety study of AMD3100 with GCSF to increase peripheral blood stem cells (NCT00291811). ClinicalTrials.gov Web site, February 6, 2007.
102. Study evaluating the safety and efficacy of AMD3100 for transplantation of sibling donor stem cells in patients with hematological malignancies (NCT00241358). ClinicalTrials.gov Web site, February 6, 2007.
103. AMD3100 with busulfan, fludarabine and thymoglobulin for allogeneic stem cell transplant for AML and MDS (NCT00396968). ClinicalTrials.gov Web site, February 6, 2007.
104. AMD3100 with G-CSF in poor mobilizing adult patients who previously failed HSC collection/attempts (NCT00396331). ClinicalTrials.gov Web site, February 6, 2007.
105. AMD3100 given to NHL and MM patients to increase the number of PBSCs when given a mobilizing regimen of G-CSF (NCT00396266). ClinicalTrials.gov Web site, February 6, 2007.
106. AMD3100 to mobilize stem cells for donation (NCT00075335). ClinicalTrials.gov Web site, February 6, 2007.